Fact-checked by the Peptide Authority Editorial Board · Last reviewed:
Safety Centre
Peptide red flag glossary
An A-Z of marketing phrases used by unlicensed peptide sellers, online clinics, and counterfeit-pen vendors targeting UK consumers. Each entry has the phrase and what it usually actually means. Use this as a decoder when reading peptide advertising.
A single red-flag phrase isn’t necessarily proof of bad intent — context matters. Two or more from the list below, on the same product or clinic, usually is.
- ‘100% bioidentical’
- Marketing phrase with no regulatory definition. Doesn't indicate quality, sterility, or licensed-medicine status.
- ‘As featured in [publication]’
- Often fabricated. Verify the source link; many of these citations don't exist.
- ‘Bioactive’ / ‘bioavailable’
- Vague benefit framing. Says nothing about safety, dose, or licensed status.
- ‘Bulk discount’
- Consumer-supply framing for a medicine. Real prescriptions are dispensed per-patient, not in bulk.
- ‘Cell-signalling optimisation’
- Marketing language without a defined clinical meaning. Implies cellular benefit without claiming a specific indication (so as not to trigger advertising rules).
- ‘Clinical-grade’
- Not a defined regulatory standard. Doesn't mean GMP-manufactured or batch-tested.
- ‘Compounded’
- Lawful UK compounding (‘specials’) is narrow and prescriber-led. ‘Compounded’ in mass-market marketing usually means unlicensed-medicine supply outside the framework — see /legal/compounded-peptides-uk.
- ‘Discreet packaging’
- Unlicensed-supply tell. UK pharmacy shipments are packaged for the patient, not for evasion.
- ‘DM for prices’
- Hiding pricing forces conversation off-platform. Legitimate pricing is published.
- ‘FDA-approved’ (for a UK consumer)
- FDA approval is for the US market. Doesn't make a product UK-licensed.
- ‘For research purposes only’
- The label doesn't change the regulatory analysis when sold with dosing instructions to consumers. See /legal/not-for-human-consumption-claims.
- ‘Guaranteed results’
- Per-se CAP code breach for health claims. Honest clinics don't guarantee outcomes.
- ‘Limited stock — order now’
- Urgency framing common in counterfeit and unlicensed-supply marketing.
- ‘Lose [X] kg in [Y] weeks’
- Specific guaranteed weight-loss outcomes for an individual are CAP slimming code breaches.
- ‘Natural’ / ‘organic peptide’
- ‘Natural’ has no meaning for a synthetic peptide. Marketing fluff.
- ‘No consultation needed’
- Skipping clinical assessment is what makes prescription supply unlawful AND unsafe.
- ‘No prescription required’
- For a POM, this is direct evidence that the supply is unlawful.
- ‘Not for human consumption’
- See ‘for research purposes only’. The label is marketing hygiene, not a regulatory shield.
- ‘Our doctor will issue a prescription’
- Question whether the doctor actually assesses, names themselves, and follows up. The prescription paperwork doesn't make supply lawful on its own.
- ‘Our EU pharmacy partner’ / ‘shipped from [non-UK]’
- Cross-border supply has been the consistent UK counterfeit-pen route.
- ‘Pharmaceutical grade’
- Not a defined standard for unlicensed compounds. Real pharmaceutical-grade material comes from licensed manufacturers — and is sold as a finished licensed product, not a research vial.
- ‘Regenerative medicine’ / ‘regenerative therapy’
- Marketing language. ‘Regenerative’ for unlicensed peptide use is a medicinal claim that triggers MHRA scrutiny.
- ‘Research-grade’ / ‘lab-grade’
- Unlicensed-medicine supply when sold to consumers with dosing instructions.
- ‘Same active ingredient at half the price’
- The price gap usually reflects skipped quality assurance. The regulated supply chain costs the missing half.
- ‘Same as [licensed brand]’
- ‘Same as Wegovy’ from a research-chemical seller is almost certainly unlicensed-medicine supply, not the licensed product.
- ‘Subscription model — auto-renew’
- Locks in sales without a clinical re-assessment. Not a substitute for ongoing prescriber review.
- ‘Used by professional athletes’
- Athlete imagery for unlicensed substances is recurring ASA case material AND creates direct anti-doping issues.
What to do when you see them
- Don’t pay yet. Run the seller through the ‘before you buy online’ checklist.
- For a clinic offer, run it through the ‘too good to be true’ tests.
- Report patterns of red-flag marketing to ASA and (where unlicensed-medicine supply is implied) MHRA. See peptide advertising rules for the routes.
Sources & further reading
- ASA / CAP advertising codes — asa.org.uk
- MHRA — gov.uk
- Report a problem with a medicine or medical device — gov.uk
- Human Medicines Regulations 2012 — legislation.gov.uk